Terms: = Leukemia AND DEK, D6S231E, 7913, ENSG00000124795, P35659 AND Treatment
17 results:
1.
Choi YJ; Min YK; Lee ST; Choi JR; Shin S
Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
[TBL] [Abstract] [Full Text] [Related]
2. [Analysis of 7 cases of pediatric acute myeloid leukemia with dek-NUP214 fusion gene].
Li XL; Liu LP; Wan Y; Liu F; Chen X; Ren YY; Ruan M; Guo Y; Zhu XF; Yang WY
Zhonghua Er Ke Za Zhi; 2023 Apr; 61(4):357-362. PubMed ID: 37011983
[No Abstract] [Full Text] [Related]
3. Inhibition of dek Enhances Doxorubicin-Induced Apoptosis and Cell Cycle Arrest in T-Cell Acute Lymphoblastic leukemia Cells.
Tian X; Zhu Z; Wang G; Xu J; Liang A; Zhang W
Dis Markers; 2022; 2022():9312971. PubMed ID: 35769815
[TBL] [Abstract] [Full Text] [Related]
4. Decitabine combined with medium-dose cytarabine in the treatment of dek/CAN-positive acute myeloid leukemia: a case report.
Zhang X; Zhang X
Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
[TBL] [Abstract] [Full Text] [Related]
5. Acute Myeloid leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy.
Conneely SE; Stevens AM
Curr Oncol Rep; 2021 Jan; 23(2):16. PubMed ID: 33439382
[TBL] [Abstract] [Full Text] [Related]
6. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract] [Full Text] [Related]
7. LCMR1 interacts with dek to suppress apoptosis in lung cancer cells.
Xu Y; Liang Z; Li C; Yang Z; Chen L
Mol Med Rep; 2017 Oct; 16(4):4159-4164. PubMed ID: 28765911
[TBL] [Abstract] [Full Text] [Related]
8. [Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
Liu GM; Zhang LJ; Fu JZ; Liang WT; Cheng ZY; Bai P; Bian YS; Wan JS
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):140-145. PubMed ID: 28279039
[No Abstract] [Full Text] [Related]
9. Transformation of human CD34+ hematopoietic progenitor cells with dek-NUP214 induces AML in an immunocompromised mouse model.
Qin H; Malek S; Cowell JK; Ren M
Oncogene; 2016 Oct; 35(43):5686-5691. PubMed ID: 27065320
[TBL] [Abstract] [Full Text] [Related]
10. The kinetics of relapse in dek-NUP214-positive acute myeloid leukemia patients.
Ommen HB; Touzart A; MacIntyre E; Kern W; Haferlach T; Haferlach C; Tobal K; Hokland P; Schnittger S
Eur J Haematol; 2015 Nov; 95(5):436-41. PubMed ID: 25605311
[TBL] [Abstract] [Full Text] [Related]
11. Nucleoporins and nucleocytoplasmic transport in hematologic malignancies.
Takeda A; Yaseen NR
Semin Cancer Biol; 2014 Aug; 27():3-10. PubMed ID: 24657637
[TBL] [Abstract] [Full Text] [Related]
12. [Application of multiplex nested RT- PCR assay for screening the fusion genes in acute myeloid leukemia and its clinical significance].
Xu Y; Gao L; Sun J; Ding Y; Xu Y; Lyu C; Liu W; Wang N; Wang L; Yu L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):29-34. PubMed ID: 24602728
[TBL] [Abstract] [Full Text] [Related]
13. Forced expression of the dek-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract] [Full Text] [Related]
14. p300/CBP-associated factor drives dek into interchromatin granule clusters.
Cleary J; Sitwala KV; Khodadoust MS; Kwok RP; Mor-Vaknin N; Cebrat M; Cole PA; Markovitz DM
J Biol Chem; 2005 Sep; 280(36):31760-7. PubMed ID: 15987677
[TBL] [Abstract] [Full Text] [Related]
15. Development of a D-FISH method to detect dek/CAN fusion resulting from t(6;9)(p23;q34) in patients with acute myelogenous leukemia.
Shearer BM; Knudson RA; Flynn HC; Ketterling RP
Leukemia; 2005 Jan; 19(1):126-31. PubMed ID: 15510206
[TBL] [Abstract] [Full Text] [Related]
16. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated dek-CAN fusion peptide.
Ohminami H; Yasukawa M; Kaneko S; Yakushijin Y; Abe Y; Kasahara Y; Ishida Y; Fujita S
Blood; 1999 Feb; 93(3):925-35. PubMed ID: 9920842
[TBL] [Abstract] [Full Text] [Related]
17. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review.
Potter MN; Cross NC; van Dongen JJ; Saglio G; Oakhill A; Bartram CR; Goldman JM
Leukemia; 1993 Aug; 7(8):1302-14. PubMed ID: 8350633
[TBL] [Abstract] [Full Text] [Related]
